Europe

Three cross-cutting dynamics define Europe this quarter. First, the region is splitting into two access regimes. Classical psychedelics remain controlled, research-led, and in many countries formally unavailable outside clinical trials or exceptional routes, but esketamine has become the medically legible pathway that health systems can actually reimburse and operationalise. That is visible in Denmark, where Medicinraadet recommended esketamine in November 2025 for a defined treatment-resistant depression subgroup and acute suicidal-risk care, in France where ANSM created a March 2026 compassionate framework for IV racemic ketamine in severe suicidal ideation, and in the Netherlands, Spain, Portugal and Austria, where public financing and specialist-use frameworks continue to centre on esketamine rather than psilocybin. This is not a pan-European liberalisation story, it is a hospital-psychiatry normalisation story.

Second, Europe’s regulatory motion is increasingly about exceptional pathways, not full authorisations. Germany is the clearest example: BfArM publicly lists a psilocybin compassionate-use cohort for treatment-resistant depression running from 11 July 2025 to 11 July 2026, which gives the country a formal but time-limited bridge between trial evidence and routine approval. Switzerland continues to use a case-by-case FOPH exceptional-permission model, with the 2025 BAG expert report citing roughly 700 permits in 2024 and about 100 treating physicians, showing that controlled medical access can scale modestly without becoming general access. Czechia moved further than most peers, because therapeutic psilocybin became lawful from 1 January 2026, but only inside specialised services and only after standard options fail or are not tolerated. These are different legal mechanisms, but they point in the same regional direction: Europe is building managed exceptions before it is willing to contemplate broad prescribing.

Third, the research map is becoming more clustered and more translational. Blossom tracks 10 psychedelic clinical trials connected to Finland and 8 connected to Sweden, with visible compound overlap around esketamine, ketamine and psilocybin, which suggests that the Nordic region is increasingly important as a controlled clinical-research corridor rather than a patient-access market. Denmark’s Copenhagen programme around alcohol use disorder remains one of the cleanest European psilocybin signals, while the Netherlands’ PsyPal project, coordinated by UMCG and funded under Horizon Europe, gives the region an EU-backed palliative-care anchor. In Germany, EPIsoDE has now been published, and in France the PAD pilot at CHU Nîmes has moved the field from feasibility language to reported randomised data. In the UK, the research base remains deepest, but the policy work is still about reducing Schedule 1 friction rather than creating routine clinical access. Europe’s research centre of gravity is therefore not disappearing, it is concentrating around a handful of highly capable hospital-university nodes.

Fourth, the regional policy frame is being shaped by EU-level medicines governance even where individual substances stay nationally controlled. The EMA’s 2026 work on pharmaceutical reform, together with its new pilot for breakthrough medical devices, matters because psychedelic medicine is increasingly intertwined with service-delivery infrastructure, monitoring tools, and supervised administration workflows, not just with the active molecule. That is especially relevant in countries where access is likely to remain hospital-based, such as France, Spain, the Netherlands and the UK. The practical implication is that Europe’s next phase is likely to be defined by service models, supervision standards and evidence packages, rather than by a single decisive scheduling reform.

Across the region, the most important signal is not that psychedelic medicine has become easier, but that European systems are becoming more explicit about where, how and for whom these treatments may be considered. That clarity is uneven, and often narrow, but it is new enough to matter.

Over the next 12 to 24 months, Europe is likely to move further along a two-speed path. On one side, esketamine and ketamine-based care should continue to expand through hospital psychiatry, reimbursement updates, and service-level decisions in countries such as Denmark, the Netherlands, Spain, France and Portugal. This will not be uniform, but it will be practical: more defined pathways, more institutionally supported use, and clearer payer logic. On the other side, classical psychedelics are more likely to advance through evidence accumulation and exceptional permissions than through broad legalisation.

Germany is the most important watchpoint because its psilocybin compassionate-use cohort is time-limited, so renewal or replacement after July 2026 will signal whether the country sees exceptional access as a bridge or a dead-end. Czechia is the most important implementation story: the legal framework is in place, but the operational details, product supply, trained teams, and specialised-site capacity will determine whether it becomes a real clinical route. Switzerland should remain a controlled-access laboratory, with FOPH permits and institutional expertise likely to set the pace. The Netherlands, France and the UK will probably be judged less by headline law changes than by whether current trials, reimbursement reviews and hospital frameworks translate into durable pathways.

The region’s biggest near-term upside is not a sweeping regulatory shift, but a gradual tightening of standards around who can provide these treatments, in what settings, and with what evidence. That is a slower story, but for Europe it is probably the more durable one.